The tyrosine kinase c-Src is upregulated in various human cancers; however, the molecular mechanisms underlying c-Src-mediated tumor progression remain unclear. Here we show that downregulation of microRNA (miR)-542-3p is tightly associated with tumor progression via c-Src-related oncogenic pathways. In c-Src-transformed fibroblasts and human cancer cells that overexpress c-Src, miR-542-3p is substantially downregulated, and the ectopic expression of miR-542-3p suppresses tumor growth. We identified the integrin-linked kinase (ILK) as a conserved target of miR-542-3p. ILK upregulation promotes cell adhesion and invasion by activating the integrin-focal adhesion kinase (FAK)/c-Src pathway, and can also contribute to tumor growth via the AKT and glycogen synthase kinase 3b pathways. MiR-542-3p expression is downregulated by the activation of c-Src-related signaling molecules, including epidermal growth factor receptor, K-Ras and Ras/ Raf/mitogen-activated protein kinase/extracellular signalregulated kinase. In human colon cancer tissues, downregulation of miR-542-3p is significantly correlated with the upregulation of c-Src and ILK. Our results suggest that the novel c-Src-miR-542-3p-ILK-FAK circuit plays a crucial role in controlling tumor progression.
Introduction
The tyrosine kinase c-Src plays an important role in cell proliferation, survival, adhesion and migration, which are all processes that are tightly associated with tumor progression (Brown and Cooper, 1996; Ingley, 2008) . c-Src is frequently overexpressed and activated in a wide variety of human cancers, suggesting that it actively facilitates tumor progression (Frame, 2002; Ishizawar and Parsons, 2004; Yeatman, 2004) . In normal cells, the kinase activity of c-Src is rigorously controlled by the negative regulator, C-terminal Src kinase (Csk) (Okada et al., 1991) ; thus, even when c-Src is abundantly expressed, its oncogenic potential is suppressed. The c-src gene is rarely mutated, but c-Src function is nonetheless upregulated in some cancer cells (Irby et al., 1999; Irby and Yeatman, 2000) . Therefore, it has been hypothesized that disruption of the strict regulation of c-Src signaling triggers cancer progression, although the underlying mechanisms remain unclear.
Once activated by extracellular signals such as growth factors and integrins, c-Src acts as a common upstream regulator of multiple oncogenic pathways, including the Ras/MAPK pathway and phosphoinositide 3-kinase pathways (Ingley, 2008) , which induce the phenotypic changes characteristic of transformation and malignancy. Mounting evidence has demonstrated the importance of c-Src in cancer progression, but the perturbation of the regulatory system of c-Src signaling during cancer progression remains to be elucidated in detail.
Downstream signaling pathways involved in cell transformation and tumor progression, including focal adhesion kinase (FAK), Src family kinase, extracellular signal-regulated kinase (ERK) and AKT, can be activated by integrin-mediated cell-extracellular matrix adhesion (Mitra and Schlaepfer, 2006; Hehlgans et al., 2007) . Integrin-linked kinase (ILK) is a kinase and adaptor protein that localizes to focal adhesions. ILK couples integrins and growth factor receptors to intracellular signaling events such as actin cytoskeletal reorganization, survival, proliferation, cell migration, invasion and epithelial-to-mesenchymal transition (Hannigan et al., 1996; Attwell et al., 2003; Persad and Dedhar, 2003; McDonald et al., 2008) . ILK activity is positively modulated, in a phosphoinositide 3-kinasedependent manner, by both cell-ECM interactions and growth factor receptors. ILK is subsequently able to phosphorylate glycogen synthase kinase 3b (GSK3b) and AKT and regulate their activity (Yoganathan et al., 2000; Hannigan et al., 2005; Cabodi et al., 2010a, b) . In addition, overexpression of ILK leads to a number of oncogenic phenotypes, such as anchorage-independent growth, cell migration and invasion (Radeva et al., 1997; Persad and Dedhar, 2003) . Conversely, ILK inhibition suppresses the proliferation and invasive activity of cancer cells (Yau et al., 2005; Troussard et al., 2006) . Further, data from mouse models in which ILK is overexpressed (White et al., 2001) or ablated (Pontier et al., 2010) in mammary gland epithelium have demonstrated that ILK functions in tumor growth and metastasis. ILK overexpression and deregulation are frequently observed in a wide variety of human cancers, further implicating ILK in tumorigenesis and cancer progression (Yoganathan et al., 2000; McDonald et al., 2008) . Although it is known that ILK protein is stabilized through binding to PINCH (particularly interesting Cys-His-rich protein) (Legate et al., 2006) and that ILK transcription is regulated by peroxisome proliferator-activated receptor (Di-Poi et al., 2002; Yang et al., 2010) , the mechanisms of ILK upregulation in cancer cells are poorly understood.
MicroRNAs (miRNAs or miR) are endogenous noncoding RNAs of approximately 22 nucleotides that bind to complementary sequences within mRNAs, thereby either inhibiting translation or causing mRNAs to become degraded. (Ambros, 2004; Bartel, 2004 Bartel, , 2009 Ventura and Jacks, 2009) . More than 1000 different miRNAs have been identified in humans so far. miRNAs control diverse cellular functions, including cell proliferation and differentiation (He and Hannon, 2004; Bartel, 2009 ). Owing to their 'fine-tuning' modulatory capabilities, miRNAs are emerging as important regulators in various signaling pathways involved in development and cancer progression. Each miRNA is predicted to target hundreds of genes, and each transcript may in turn interact with multiple miRNAs (Bartel, 2009) . Numerous recent studies have demonstrated abnormal miRNA expression patterns in human cancers, with the consequent alteration in the expression of target oncogenes or tumor suppressor genes (Calin and Croce, 2006; Esquela-Kerscher and Slack, 2006) . These lines of evidence strongly suggest that miRNAs function in tumor promotion and suppression (Shenouda and Alahari, 2009) .
To address the molecular mechanisms underlying c-Src-mediated cell transformation, we developed a model system using Csk-deficient mouse embryonic fibroblasts (Csk À/À cells) that can be transformed by wild-type c-Src (Oneyama et al., 2008) . In this system, the activation of relatively small numbers of molecules is sufficient for the induction of cell transformation and tumorigenesis. These findings suggest that this system could be useful in the identification of critical pathways leading to c-Src transformation. Recently, we used this experimental system to analyze the potential contribution of miRNAs to c-Src-mediated tumor growth. Expression profiling of miRNAs in Csk À/À cells revealed that a specific set of miRNAs is differentially regulated by c-Src transformation (Oneyama et al., 2011) . Here, we focused our analysis on miR-542-3p, based on its considerable downregulation following c-Src transformation. We found that miR-542-3p is downregulated in a variety of human cancers and directly targets ILK. Functional analysis of miR-542-3p suggests that miR-542-3p is downregulated via the c-Src-related oncogenic pathway, and functions as a suppressor of tumor progression by controlling ILK-mediated cell adhesion and invasion.
Results miR-542-3p serves as a suppressor of c-Src-induced tumor growth We previously found that c-Src-transformed Csk À/À cells exhibited appreciable downregulation of a set of miRNAs that include miR-23b, -27b, -99a -322, -450a, -503 and -542-3p , and showed that miR-99a is involved in controlling tumor growth by suppressing the expression of mammalian target of rapamycin /fibroblast growth factor receptor 3 (Oneyama et al., 2011) . To further evaluate the contribution of other miRNAs to c-Src transformation, we focused our analysis on miR-542-3p, whose function is as yet poorly characterized, although its potential tumor-suppressive role has been observed in a human cancer cell line (Yoon et al., 2010) .
We first analyzed the function of miR-542-3p by ectopically expressing miR-542-3p in c-Src-transformed Csk À/À cells. Overexpression of miR-542-3p significantly suppressed cell growth (Supplementary Figure S1 ) and anchorage-independent growth of c-Src-transformed cells in an miRNA dose-dependent manner ( Figure 1a) . Tumorigenesis of c-Src-transformed cells in nude mice was also significantly suppressed by the expression of miR-542-3p (Figure 1b) . Interestingly, when we inactivated miR-542-3p using anti-miR-542-3p, untransformed Csk À/À cells, which express higher levels of miR-542-3p than transformed cells (Figure 2d ), acquired the ability to form colonies in soft agar ( Figure 1c ). These results indicate that miR-542-3p functions as a suppressor of c-Src-induced tumor growth.
ILK is a conserved target of miR-542-3p
A previous study used a bioinformatic search (TargetScan) and a microarray analysis to identify the potential miR-542-3p target genes (Yoon et al., 2010) . Among the predicted targets, survivin, a member of the inhibitor of apoptosis family, was shown to be a direct target of miR-542-3p in a human cancer cell line. However, this miRNA-target relationship is not evolutionarily conserved outside the primates. Survivin expression is suppressed by miR-542-3p in human cancer cells, but was not affected by either miR-542-3p or antimiR-542-3p in mouse Csk À/À cells (Supplementary Figure S2) . Nonetheless, the introduction of miR-542-3p readily suppressed tumor growth of these mouse cells (Figure 1 ). Thus, we further searched for more general targets in more broadly conserved targets predicted by TargetScan. Among the candidates, ILK and DCBLD2 (Discoidin, CUB and LCCL domain containing 2) were identified as targets likely to be involved in tumor growth, based on previous reports (McDonald et al., miR-542-3p controls c-Src-mediated malignancy C Oneyama et al 2008; Kim et al., 2008a) . However, as DCBLD2 is downregulated by DNA hypermethylation in human cancers (Kim et al., 2008a) , we asked whether ILK might be regulated by miR-542-3p. A luciferase reporter assay in c-Src-transformed cells showed that introduction of miR-542-3p significantly suppressed the expression of the ILK reporter by specifically targeting the predicted miR-542-3p binding sequences in the 3 0 -untranslated region of the ILK mRNA (Figures 2a and b, left panel) . Inversely, the inactivation of miR-542-3p by anti-miR-542-3p enhanced the expression of the ILK reporter in untransformed Csk À/À cells ( Figure 2b , right panel). Western blot analysis showed that ILK protein was upregulated by c-Src transformation (Figure 2c , lane 1 vs 3) and was significantly downregulated by the expression of miR-542-3p (lane 3 vs 4). In contrast, the introduction of anti-miR-542-3p increased ILK expression (lane 1 vs 2). In addition to ILK protein expression, the activity of AKT and GSK3b, critical downstream effectors of ILK, was also regulated by miR-542-3p (Figure 2c ). Quantitative real-time-polymerase chain reaction (qRT-PCR) analyses showed that introduction of miR-542-3p substantially reduced the expression of ILK mRNA and ILK protein to the same extent ( Figure 2c, right panel) . Thus, miR-542-3p downregulates ILK protein levels by directing mRNA degradation. Furthermore, the level of ILK expression was inversely correlated with the level of miR-542-3p expression, depending on the levels of c-Src activity in
Csk
À/À cells ( Figure 2d ). These findings demonstrate that miR-542-3p directly targets ILK, and that downregulation of miR-542-3p is associated with the upregulation of ILK in c-Src-transformed cells.
miR-542-3p regulates tumor growth of human cancer cells
To examine whether ILK is also regulated by miR-542-3p in human cancers, the expression levels of miR-542-3p and ILK were measured in several human colon cancer cell lines that overexpress c-Src. The qRT-PCR analysis for miR-542-3p revealed that the expression of miR-542-3p was greatly reduced in most colon cancer cells compared with those in normal cells (Figure 3a ). Western blot analysis showed a significant upregulation of ILK in all of the colon cancer cell lines, inversely correlated with miR-542-3p expression ( Figure 3b ). To confirm the functional link between miR-542-3p and ILK, we ectopically expressed miR-542-3p in HCT116 and SW480 cells. Expression of miR-542-3p significantly suppressed ILK in these cells (Figure 3c ). These observations indicate that the downregulation of miR-542-3p can be observed in multiple human colon cancers, and that the expression of ILK is regulated by miR-542-3p in human cancers as well as in the mouse system.
To elucidate the role of miR-542-3p downregulation in human cancers, we examined the effects of miR-542-3p expression on the colony-forming activity 0 -untranslated region were transfected into c-Src-transformed cells. These cells were treated with Cont-miR (white) or miR-542-3p (black), and relative luciferase activity was determined (left panel). Csk À/À cells treated with anti-Cont-miR (white) or anti-miR-542-3p (black) were transfected with pMIR-ILK constructs, and relative luciferase activity was determined (right panel). Relative Renilla luciferase expression was standardized to a transfection control. Relative values±s.d. were obtained from three independent assays. *Po0.05 by Student's t-test. (c) Csk À/À cells (Mock) were transfected with control or anti-miR-542-3p, and c-Src transformed cells (c-Src) were transfected with control or miR-542-3p. Total cell lysates were immunoblotted with the indicated antibodies. The relative expression level of ILK is shown at the bottom of the panels (left panels). c-Src-transformed cells were transfected with control (white) or miR-542-3p (black) for 48 h, and levels of ILK mRNA were analyzed using real-time PCR (right panel). (d) Total lysates from Csk À/À cells were subjected to immunoblotting with the antibodies indicated (left panels). The relative expression level of ILK is shown at the bottom of the panels. The expression of miR-542-3p was analyzed using real-time PCR (right panel). Relative values±s.d. were obtained from three independent assays. miR-542-3p controls c-Src-mediated malignancy C Oneyama et al ) obtained from four mice are plotted vs time after inoculation (days). (f) HCT116 cells expressing control shRNA (sh-cont) or ILK shRNA (nos. 1 and 4) with or without sh-resistant mouse ILK were subjected to soft-agar colony-formation assay. (g) HCT116 cells transfected with ILK ORF cDNA were treated with cont-miR or miR-542-3p and subjected to soft-agar colony-formation assay. Colonies were scored 8 days after plating (f, g). The mean number of colonies±s.d. was obtained from three independent experiments. miR-542-3p controls c-Src-mediated malignancy C Oneyama et al
We next examined whether the tumor-suppressive effect of miR-542-3p is mediated by ILK downregulation. Short hairpin RNA (shRNA)-mediated ILK knockdown significantly suppressed colony-forming activity in HCT116 cells (Figure 3f ). Restoration of ILK expression using the mouse gene, which is resistant to shRNA-mediated degradation, fully restored the colony-forming activity (Figures 3f and 5c) . However, when ILK open reading frame (ORF) cDNA, which is resistant to miR-542-3p, was introduced into miR-542-3p-treated HCT116 cells, the colony-forming activity was only moderately rescued (Figures 3g and 5e ). These results suggest that ILK is able to contribute to promoting tumor growth in human cancer cells, but the growth-suppressive effect of miR-542-3p is not solely attributed to ILK downregulation.
miR-542-3p regulates cell adhesions and invasion via ILK
The moderate effects of ILK on tumor growth suggest that it may exert more specific functions in cancer cells. It is well established that ILK couples integrin signals to intracellular events such as actin cytoskeletal reorganization, survival, cell migration and invasion (McDonald et al., 2008) . Thus, we next examined the role of the miR-542-3p-ILK pathway in such cellular events by focusing on cell morphology and adhesion. The introduction of miR-542-3p in HCT116 cells induced striking morphological changes, leading to cell aggregation (Figure 4a ). Similar effects of miR-542-3p on cell morphology were also observed in other cancer cells such as SW620 cells (data not shown). Western blot analysis of HCT116 and SW620 cells showed that the downregulation of ILK by miR-542-3p was associated with the reduction of the activity of FAK (pY397) and c-Src (pY418) (Figure 4b ), both of which are crucial for controlling cell adhesion and motility downstream of integrins (Mitra and Schlaepfer, 2006) . Consistent with the reduction in c-Src activity, the levels of intracellular tyrosine phosphorylation were substantially decreased, particularly in HCT116 cells (Figure 4b ). Cell staining for paxillin, a marker of focal contact, and actin fibers (F-actin) showed that miR-542-3p-treated HCT116 cells exhibited disruption of stress fibers and reduced numbers of focal contacts (Figure 4c) . Notably, the expression of ILK ORF in miR-542-3p-treated HCT116 cells was able to nearly completely rescue cytoskeletal organization and the formation of focal contacts (Figure 4d ). These observations suggest that ILK, under the control of miR-542-3p, plays an essential role in regulating cytoskeletal organization and formation of focal contacts, and that its function is tightly linked to FAK and c-Src.
The role of the miR-542-3p-ILK pathway in controlling cell adhesion was further confirmed by cell adhesion assays. The adhesion of HCT116 cells to collagen-coated dishes was remarkably suppressed by the expression of miR-542-3p (Figure 5a ). Similar effects of miR-542-3p on cell adhesion were also observed in other cancer cells, such as SW620 cells and c-Src-transformed Csk À/À cells (Supplementary Figure S3) . shRNA-mediated ILK knockdown significantly suppressed cell adhesion, and these effects were rescued by the expression of shRNAresistant ILK (Figures 5b and c) . Likewise, introduction of the ILK ORF into miR-542-3p-treated HCT116 cells successfully restored cell adhesion (Figures 5d and e) . The strong inhibitory effect of anti-integrin b1-neutralizing antibody on cell adhesion indicated that cell adhesion was mediated by b1-integrin (Figure 5b ). These results show that the miR-542-3p-mediated regulation of ILK contributes significantly to the control of integrinmediated cell adhesion.
Consistent with the changes in cell adhesion activity, shRNA-mediated ILK knockdown decreased the activity of FAK (pY397) and GSK3b, and restoration of ILK expression in these cells induced the re-activation of these kinases (Figure 5c ). Also, the activities of FAK and c-Src (pY418) were reduced by treatment with miR-542-3p in a dose-dependent manner (Figure 5e and Supplementary Figure S4) , and the introduction of the ILK ORF into these cells caused the significant reactivation of FAK and c-Src (Figure 5e ). These results suggest that ILK is involved in the activation or stabilization of the FAK/c-Src pathway. To examine the potential interaction of ILK with FAK/c-Src, we performed immunoprecipitation assays. Depending on the levels of ILK expression, c-Src and FAK was efficiently co-precipitated with ILK, suggesting a direct interaction between these molecules (Supplementary Figure S5) . Because ILK and the integrin-FAK/c-Src pathway regulate invasiveness in cancer cells (McDonald et al., 2008) , we assessed the in vitro invasive potential of miR-542-3p-treated HCT116 cells in a Matrigel-based assay. The introduction of miR-542-3p potently suppressed the invasive activity of these cells (Figure 5f ). Overall, these findings suggest that the miR-542-3p-ILK-FAK/c-Src pathway plays crucial roles in controlling integrin-mediated cell adhesion and invasion in cancer cells. miR-542-3p expression is downregulated by the activation of c-Src-related oncogenic signaling Furthermore, to determine whether miR-542-3p expression can be regulated under physiological conditions, we stimulated mouse embryonic fibroblasts with epidermal growth factor (EGF) and assessed changes in miR-542-3p expression. EGF stimulation induced an apparent downregulation of miR-542-3p expression and a consequent upregulation of ILK expression (Figure 6a ). Using this system, we next examined the signaling pathways, leading to miR-542-3p downregulation. Treatment with Dasatinib, a potent Src inhibitor, almost completely blocked the EGF-induced downregulation of miR-542-3p expression. Treatment with a Ras/Raf/ mitogen-activated protein kinase (MEK) inhibitor (U0126) was also able to suppress potently the downregulation of miR-542-3p, whereas a phosphoinositide 3-kinase inhibitor (LY294002) was not effective (Figure 6a ). These pharmacological analyses suggest that miR-542-3p expression is mainly regulated via the MEK/ERK pathway. As the MEK/ERK pathway is miR-542-3p controls c-Src-mediated malignancy C Oneyama et al activated by Ras, which is frequently mutated in various human cancers, we analyzed miR-542-3p expression in Ras-transformed cells. As expected, transformation by Ras, particularly by K-Ras, induced a significant downregulation of miR-542-3p to a level similar to that observed in c-Src-transformed cells (Figures 2d and 6b ). These findings suggest that the expression of miR-542-3p
is downregulated via the MEK/ERK pathway downstream of activated EGFR, c-Src and/or K-Ras.
miR-542-3p is downregulated in human cancer tissues
Finally, the role of miR-542-3p in human cancers was examined by assessing miR-542-3p expression in miR-542-3p controls c-Src-mediated malignancy C Oneyama et al primary colon tumors and adjacent normal tissues using qRT-PCR. Five primary tumors were classified into two histological types: nos. 1, 2 and 3 were moderately differentiated cancers, whereas nos. 4 and 5 were well-differentiated cancers. In four of the five tumor samples, miR-542-3p was significantly downregulated miR-542-3p controls c-Src-mediated malignancy C Oneyama et al ( Figure 7a ). Moreover, western blot analysis of the tissue samples showed that ILK expression was higher in tumors than in normal tissue in the three moderately differentiated cases (nos. 1, 2 and 3), which all exhibited miR-542-3p downregulation (Figure 7b ). These observations suggest that there is an inverse correlation between the expression of miR-542-3p and ILK in human cancer tissues as well as human cancer cells (Figures 3a and b) . To determine whether ILK upregulation via miR-542-3p is associated with c-Src activation in human cancer tissues, immunohistochemistry for ILK and activated cSrc (pY418) was performed in 10 other colon tumor specimens. Compared to adjacent normal tissues, levels of ILK were upregulated in 7 of 10 primary tumor regions. Of note, activated c-Src immunoreactivity (pY418) was greatly increased in six of the seven tumor specimens in which ILK was upregulated (Figure 7c ). These observations further support our hypothesis that there is a correlation between the ILK expression and c-Src activation in human cancer tissues.
To further confirm the importance of miR-542-3p, we examined human cancer miRNA profiles available at the Gene Expression Omnibus. As the expression level of miR-542-3p is very low, only a few data sets include expression measurements for miR-542-3p. We chose two microarray data sets (GSE14857 and GSE16025) from among the available miRNA profiles for malignant cancer tissues, and re-analyzed them (see Materials and methods). In 10 of 12 malignant prostate tissues (GSE14857), miR-542-3p was significantly downregulated in comparison to matched normal prostate tissues (P ¼ 0.0448; Figure 7d) . A similar tendency was observed in lung carcinoma (GSE16025) (Supplementary Figure S6 ). These observations suggest that downregulation of miR-542-3p might be associated with a wide array of human cancers.
Discussion
This study revealed that miR-542-3p is a crucial mediator of the oncogenic potential of c-Src. A schematic model for the miR-542-3p-mediated regulation of cancer progression is depicted in Figure 7e . When c-Src is upregulated, as in some cancers, or activated by external stimuli such as EGF and extracellular matrix, miR-542-3p is downregulated. The downregulation of miR-542-3p results in ILK upregulation, which induces AKT/GSK3b-mediated cell survival and also promotes activation of c-Src/FAK-mediated tumorigenic and invasive activity. These findings suggest that c-Srcmediated miR-542-3p downregulation initiates a positive feedback loop that activates c-Src by inducing ILK expression; this loop may contribute broadly to promotion of cancer malignancy.
We recently identified seven miRNAs, miR-23b, -27b, -99a, -322, -450a-5p, -503 and -542-3p, that were downregulated by c-Src transformation in Csk À/À cells (Oneyama et al., 2011) . In a previous study, it was indicated that miR-126, -218 and -224 were implicated in v-Src transformation (Li et al., 2009 ). Moreover, it was shown that miR-21 and miR-181b-1 were differentially miR-542-3p controls c-Src-mediated malignancy C Oneyama et al expressed during transformation of MCF10A-ER-Src cells (Iliopoulos et al., 2010) . However, the miRNAs reported in these studies are not necessarily consistent with those identified in our study. This inconsistency might be due to the difference in the pathways activated by v-Src and c-Src, or related to the cellular context. Because upregulation of c-Src expression and/or activity, rather than gain-of-function mutations in the c-src gene, widely contributes to the progression of human cancers, we used c-Src-transformed cells to identify miRNAs crucial for regulating human cancers. Of seven miRNAs we identified, miR-542-3p was focused here, because its function was poorly defined, largely due to its relatively low levels of expression. A previous study showed that miR-542-3p was downregulated in matched ectopic endometrium compared to eutopic and normal endometrium (NE), implicating it in the pathogenesis of endometriosis (Toloubeydokhti et al., 2008) . More recently, miR-542-3p was shown to target survivin and inhibit proliferation by inducing cell cycle arrest, suggesting a potential role for miR-542-3p in control of human cancer growth (Yoon et al., 2010) . However, survivin is an evolutionarily non-conserved target of miR-542-3p, and it did not serve as a target in c-Srctransformed mouse embryonic fibroblasts (Supplementary Figure S2 ). Nonetheless, introduction of miR-542-3p was able to suppress potently the growth of c-Src-transformed mouse cells (Figure 1 ), implying that miR-542-3p has other critical and conserved targets involved in controlling tumor growth. Here, we analyzed the function of one such critical target, ILK, based on the potential relevance of this protein to human cancer (McDonald et al., 2008) . We found that miR-542-3p is substantially downregulated in multiple human colon cancer cell lines in which c-Src is upregulated in an inverse correlation with ILK expression. Re-introduction of miR-542-3p in these cells downregulated ILK expression and suppressed tumorigenesis, cell adhesion and in vitro invasive activity. The downregulation of miR-542-3p, which correlated with ILK upregulation, was also detected in a subset of human colon tumors. Immunohistochemical analysis of human colon tumors further revealed that there was a significant correlation between ILK upregulation and c-Src activation. In addition, the miR-542-3p-mediated ILK downregulation induced the inactivation of c-Src and FAK in human cancer cells, which was reversed by the expression of ILK; this suggests that ILK is required for activation of the c-Src/ FAK function. These lines of evidence demonstrate strong correlations between c-Src, miR-542-3p, ILK and human cancers, and suggest that miR-542-3p downregulation is involved in cancer progression in vivo not only via upregulation of ILK itself, but also via activation of the FAK/c-Src pathway.
In addition to the suppressive effect on tumor growth, the expression of miR-542-3p induced robust inhibition of the integrin-mediated cell adhesion. The re-expression of ILK in miR-542-3p-treated cancer cells significantly rescued the ability of cell adhesion, although it had more moderate effects on tumor growth. Therefore, it is likely that ILK is a target of miR-542-3p that is preferentially involved in cell adhesion signals. Earlier studies showed that Src and ILK play a critical role in integrinassociated signaling (Hehlgans et al., 2007) , and that physical interaction of ILK with c-Src affects ILK function during normal cell adhesion (Kim et al., 2008b) . In this study, we showed that ILK is required to stabilize the activation of c-Src/FAK, and is crucial for in vitro invasive activity of cancer cells. These findings suggest that miR-542-3p-mediated ILK upregulation contributes significantly to promoting c-Src/ FAK-mediated cancer invasiveness. On the other hand, it is known that the FAK/c-Src pathway can produce growth signals via the MAPK pathway (Mitra and Schlaepfer, 2006) , and that direct downstream effectors of ILK, such as AKT and GSK3b, also participate in cell survival and tumor progression (Cabodi et al., 2010a) . The partial contribution of ILK to tumor growth control may be attributed to these functions. However, the insufficient role of ILK in tumor growth suggests that there exist additional miR-542-3p targets that are required for complete control of tumor growth. Further analysis of the contribution of such additional targets will be necessary to elucidate the whole picture of miR-542-3p function.
Our study shows that the expression of miR-542-3p can also be downregulated via the c-Src-related oncogenic pathways that include EGFR, c-Src, K-Ras and MEK/ERK. This may account for the frequent downregulation of miR-542-3p in various human cancers, many of which harbor mutations in these oncogenes that confer increased pathway activity. Indeed, analysis of miRNA profiles in human cancers showed that miR-542-3p was significantly downregulated in malignant prostate cancers and lung carcinoma. These observations suggest that the upregulation of c-Src activity observed in various human cancers may be induced via a miR-542-3p-ILK-mediated positive feedback loop that can be initiated by any one of a number of oncogenes. ILK expression is also elevated in a wide variety of human cancers; strong ILK expression is associated with poor prognosis in several types of cancers (Hannigan et al., 2005; McDonald et al., 2008) . However, the mechanisms underlying this elevated ILK expression remained unclear. Previous studies showed that ILK expression can be upregulated by hypoxia (Abboud et al., 2007) , inhibition of ubiquitin-mediated degradation through binding to PINCH (Legate et al., 2006) or peroxisome proliferator-activated receptor-mediated transcriptional repression (Yang et al., 2010) . These data suggest that the cause of ILK upregulation may vary depending on tumor type. In this study, we provided clear evidence that the elevated expression of ILK in various cancers can be accounted for in some, if not all, cases by the frequent downregulation of miR-542-3p via the activation of oncogenic signals.
In conclusion, we have demonstrated a crucial role for the Src-miR-542-3p-ILK-Src loop in controlling the progression of a wide array of human cancers. As the Src-related oncogenic pathway is frequently activated in human cancers, the functional analysis of miR-542-3p controls c-Src-mediated malignancy C Oneyama et al the Src-miR-542-3p-ILK axis represents a leap forward in our understanding of cancer etiology. Our study provides insights into the function of this new signaling axis, and offers new opportunities for therapeutic intervention in cancer.
Materials and methods

Immunohistochemistry
Histological specimens were fixed in 10% formalin and routinely processed for paraffin embedding. Histological sections 4 mm thick were stained with hematoxylin and eosin and reviewed by two pathologists (JI and EM) to define the cancerous and corresponding normal tissues. An immunoperoxidase procedure was performed on the paraffin-embedded sections as described below. After antigen retrieval, using a Pascal pressurized heating chamber (Dako A/S, Glostrup, Denmark), sections were incubated with anti-ILK or anti-c-Src (pY418) antibody diluted 1:50. Sections were then treated with a ChemMate EnVision kit (Dako). Diaminobenzidine (Dako) was used as a chromogen. As a negative control, staining was carried out in the absence of primary antibody. Stained sections were evaluated independently by two pathologists (JI and EM).
Cell adhesion assay Cells were starved overnight in serum-free medium and harvested by limited trypsin-EDTA treatment (0.25% trypsin/0.02% EDTA in phosphate-buffered saline). Cells were collected by centrifugation, re-suspended in serum-free medium and held in suspension at 37 1C for 3 h. Cells were replated on dishes coated with 5 mg/ml fibronectin or 50 mg/ml collagen I and incubated for 90 min at 37 1C. After removing the medium, the attached cells were observed under a microscope, and micrographs were used to count the number of attached cells.
Statistical analysis
Relative expression of microRNAs identified in the previous study (accession number GSE14857), including miR-542-3p, was reanalyzed. Statistical significance by paired t-test was reset at Po0.05 for all microRNAs, yielding 13 miRNAs. Hierarchical clustering was visualized using Subio Basic Plugin (v.1.10; Subio Inc., Aichi, Japan) for Windows. Differences in miR-542-3p mRNA expression levels between normal cells and squamous cell carcinoma (accession number GSE16025) were analyzed by one-tailed unpaired t-test using the Subio Basic Plug-in (v.1.10; Subio Inc) for Windows.
